Alvotech Announces Increase in Number of Own Shares

REYKJAVIK, ICELAND (February 11, 2026) — Alvotech (NASDAQ: ALVO) (the “Company”), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, has increased the Company´s share capital by an amount of one hundred and twenty-five thousand (USD 125,000) by issuing twelve million and five-hundred thousand (12,500,000) ordinary shares. The Company’s subsidiary, Alvotech Manco ehf. (the “subsidiary”), has subscribed to all of the newly issued shares for a price of USD 5.2 per share. The shares held by the subsidiary are treated as treasury shares without voting rights or dividend entitlement.

Following the above-mentioned transaction, the subsidiary will hold 16,254,005 shares in the Company, or 4.7% of issued shares, and the number of total issued shares has increased from 334,038,147 to 346,538,147 shares. The number of outstanding shares, consisting of all shares not held as treasury shares by the subsidiary, is unchanged at 330,284,142 shares.

On December 17, 2025, the Company announced that it had provided a stock lending facility to the buyers of Convertible Bonds issued by the Company, for the purpose of facilitating the Convertible Bond investors' hedging activities. The share capital increase is intended to meet the reduction in the number of treasury shares resulting from settlement of the above-mentioned lending of ordinary shares, allowing the Company to continue holding a sufficient number of shares to fulfill the Company’s commitments related to various financial obligations, including warrants, convertible financial instruments, and share-based employee compensation.

CONTACT INFORMATION – INVESTOR RELATIONS
Balaji Prasad, Chief Strategy Officer
Patrik Ling, VP Investor Relations Scandinavia (SE)
Benedikt Stefansson, VP Investor Relations and Global Communications (IS)
alvotech.ir@alvotech.com

About Alvotech
Alvotech is a biotech company, founded by Robert Wessman, focused solely on the development and manufacture of biosimilar medicines for patients worldwide. Alvotech seeks to be a global leader in the biosimilar space by delivering high quality, cost-effective products, and services, enabled by a fully integrated approach and broad in-house capabilities. Five biosimilars, to Humira® (adalimumab), Stelara® (ustekinumab), Eylea® (aflibercept), Simponi® (golimumab) and Prolia®/Xgeva® (denosumab) are already approved and marketed in global markets. Alvotech’s current development pipeline includes disclosed biosimilar candidates aimed at treating autoimmune disorders, eye disorders, respiratory disease, hematological disorders and cancer. Alvotech has formed a network of strategic commercial partnerships to provide global reach and leverage local expertise in markets that include the United States, Europe, Japan, China, and other Asian countries and large parts of South America, Africa and the Middle East. For more information, please visit www.alvotech.com.